MA51993A - Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur - Google Patents

Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur

Info

Publication number
MA51993A
MA51993A MA051993A MA51993A MA51993A MA 51993 A MA51993 A MA 51993A MA 051993 A MA051993 A MA 051993A MA 51993 A MA51993 A MA 51993A MA 51993 A MA51993 A MA 51993A
Authority
MA
Morocco
Prior art keywords
antibodies
tumor
specific cell
cell deletion
deletion
Prior art date
Application number
MA051993A
Other languages
English (en)
Inventor
Anne Goubier
Corzo Beatriz Goyenechea
Pascal Merchiers
Kevin Moulder
Sergio Quezada
Josephine Salimu
Original Assignee
Cancer Research Tech Ltd
Tusk Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1804027.9A external-priority patent/GB201804027D0/en
Priority claimed from GBGB1804029.5A external-priority patent/GB201804029D0/en
Priority claimed from GBGB1804028.7A external-priority patent/GB201804028D0/en
Application filed by Cancer Research Tech Ltd, Tusk Therapeutics Ltd filed Critical Cancer Research Tech Ltd
Publication of MA51993A publication Critical patent/MA51993A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA051993A 2018-03-13 2019-03-13 Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur MA51993A (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862642230P 2018-03-13 2018-03-13
US201862642218P 2018-03-13 2018-03-13
US201862642243P 2018-03-13 2018-03-13
US201862642248P 2018-03-13 2018-03-13
US201862642232P 2018-03-13 2018-03-13
GBGB1804027.9A GB201804027D0 (en) 2018-03-13 2018-03-13 Anti-CD25 antibody agents
GBGB1804029.5A GB201804029D0 (en) 2018-03-13 2018-03-13 Anti-CD25 antibody agents
GBGB1804028.7A GB201804028D0 (en) 2018-03-13 2018-03-13 Anti-CD25 antibody agents

Publications (1)

Publication Number Publication Date
MA51993A true MA51993A (fr) 2021-01-20

Family

ID=67903878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051993A MA51993A (fr) 2018-03-13 2019-03-13 Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur

Country Status (14)

Country Link
US (11) US11814434B2 (fr)
EP (8) EP3765505B1 (fr)
JP (8) JP7451415B2 (fr)
KR (3) KR20200131286A (fr)
CN (8) CN112020516B (fr)
AU (3) AU2019233581B2 (fr)
BR (3) BR112020016501A2 (fr)
CA (3) CA3088659A1 (fr)
CR (3) CR20200465A (fr)
MA (1) MA51993A (fr)
PE (3) PE20210289A1 (fr)
SG (3) SG11202008699WA (fr)
TW (3) TW202003034A (fr)
WO (8) WO2019175224A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
CA3020204A1 (fr) * 2016-04-07 2017-10-12 Cancer Research Technology Limited Anticorps bispecifiques du recepteur fc gamma anti-cd25 pour la depletion de cellules specifiques d'une tumeur
CN108795858A (zh) * 2017-04-28 2018-11-13 深圳宾德生物技术有限公司 高抗癌活性t细胞的筛选方法和应用
US11814434B2 (en) 2018-03-13 2023-11-14 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
EP3972997A1 (fr) * 2019-05-20 2022-03-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Nouveaux anticorps anti-cd25
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
CN115397860B (zh) 2020-05-14 2025-06-13 江苏恒瑞医药股份有限公司 抗cd25抗体、其抗原结合片段及其医药用途
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
WO2022104009A1 (fr) * 2020-11-13 2022-05-19 Rubryc Therapeutics, Inc. Anticorps anti-cd25
EP4247497A1 (fr) * 2020-11-20 2023-09-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Anticorps anti-cd25
EP4247496A1 (fr) * 2020-11-20 2023-09-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Anticorps anti-cd25
EP4255929A2 (fr) 2020-12-02 2023-10-11 Vib Vzw Agoniste de ltbr utilisé pour la polythérapie contre le cancer
US20240307541A1 (en) 2021-02-02 2024-09-19 Rakuten Medical, Inc. Methods for local and systemic treatment of cancers, tumors and tumor cells
WO2022184615A1 (fr) 2021-03-01 2022-09-09 F. Hoffmann-La Roche Ag Nouveaux biomarqueurs et leurs utilisations
WO2023016455A1 (fr) 2021-08-09 2023-02-16 南京诺艾新生物技术有限公司 Anticorps anti-cd25 humain recombinant et son utilisation
CA3228786A1 (fr) * 2021-08-25 2023-03-02 Ibio, Inc. Anticorps anti-cd25
CN117916266A (zh) 2021-09-02 2024-04-19 弗哈夫曼拉罗切有限公司 用于治疗aml的抗体
AU2022337286A1 (en) * 2021-09-03 2024-02-29 Novarock Biotherapeutics, Ltd. Bispecific binding proteins that bind cd137 and a tumor associated antigen
US20250154268A1 (en) 2022-01-17 2025-05-15 Nona Biosciences (Suzhou) Co., Ltd. Antibody targeting cd25, and preparation method therefor and use thereof
WO2023208990A1 (fr) 2022-04-26 2023-11-02 F. Hoffmann-La Roche Ag Polythérapie pour le traitement du cancer comprenant un antagoniste de l'axe fas et un antagoniste d'agent de déplétion des lymphocytes t-reg,
CN115197321B (zh) * 2022-06-02 2023-08-18 四川大学 靶向cd25的抗体及其用途
CN115181182B (zh) * 2022-06-13 2024-03-29 南京融捷康生物科技有限公司 一种人源化的抗cd25的单域抗体及其应用
CN115181181B (zh) * 2022-06-13 2024-03-29 南京融捷康生物科技有限公司 一种抗cd25的单域抗体及其应用
WO2024006965A1 (fr) * 2022-06-30 2024-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps spécifiques de cd25 et leurs utilisations
WO2024040194A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
WO2024088987A1 (fr) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Polythérapie pour le traitement du cancer
CN118240080A (zh) * 2022-12-22 2024-06-25 深圳市福元生物科技有限公司 一种cd25单域抗体、人源化抗体、及制备方法
CN116004636B (zh) * 2023-01-10 2024-03-12 广西师范大学 一种不结合红细胞的差异化cd47核酸适体及其应用
CN120584138A (zh) 2023-02-06 2025-09-02 豪夫迈·罗氏有限公司 组合疗法及其用途
AU2024234615A1 (en) * 2023-03-14 2025-08-21 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
EP4692351A1 (fr) 2023-03-29 2026-02-11 Daiichi Sankyo Company, Limited Anticorps anti-cd25 et conjugué anticorps-médicament anti-cd25
WO2024213046A1 (fr) * 2023-04-11 2024-10-17 Suzhou Transcenta Therapeutics Co., Ltd. Anticorps anti-cd25 et ses utilisations
CN121666232A (zh) 2023-05-31 2026-03-13 开普斯坦治疗公司 脂质纳米颗粒制剂和组合物
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
WO2025076127A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025149667A1 (fr) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Conjugués anticorps-médicament et leurs utilisations
WO2025179294A2 (fr) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Amplification d'ingénierie immunitaire
WO2025217452A1 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
WO2025217454A2 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables et nanoparticules lipidiques
WO2026006708A2 (fr) * 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Protéines de liaison à l'antigène anti-cd25 et leurs utilisations

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4578335A (en) * 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
CA2516028C (fr) 2003-02-14 2012-10-16 University Of Southern California Conjugues comportant une molecule ciblant le cancer liee a une chimiokine exprimee par le foie
WO2005123780A2 (fr) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
EP1814568A4 (fr) 2004-10-29 2009-08-12 Univ Southern California Poly-immunotherapie anticancereuse dans laquelle sont utilisees des molecules co-stimulatrices
GB0507696D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
CA2656700A1 (fr) 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions et procedes destines a ameliorer l'efficacite de reponses immunitaires a mediation par il-2
HRP20140081T1 (hr) 2006-08-18 2014-03-28 Novartis Ag Prlr-specifiäśna antitijela i njihova uporaba
EP1997832A1 (fr) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
RU2391401C2 (ru) 2008-02-12 2010-06-10 Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US8642292B2 (en) * 2009-09-22 2014-02-04 Probiogen Ag Process for producing molecules containing specialized glycan structures
WO2011077245A2 (fr) 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
EP2378287A1 (fr) * 2010-04-15 2011-10-19 TXCell Nouveau procédé pour l'isolement de cellules T1
KR20130048242A (ko) 2010-07-22 2013-05-09 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항-종양 항원 항체 및 이용 방법
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN105377892A (zh) * 2013-03-15 2016-03-02 艾伯维生物技术有限公司 抗cd25抗体及其用途
EP3421495A3 (fr) * 2013-03-15 2019-05-15 Xencor, Inc. Modulation de cellules t avec des anticorps bispécifiques et des fusions fc
BR112015023086A2 (pt) 2013-03-15 2017-11-21 Abbvie Biotechnology Ltd anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-cd25 ou fragmento ligante anti cd25, para prevenção de rejeição de órgãos transplantados e para tratamento de uma doença.
JP6824735B2 (ja) * 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
WO2015109212A1 (fr) * 2014-01-17 2015-07-23 Pfizer Inc. Anticorps anti-il-2 et compositions et utilisations de ceux-ci
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
GB201403775D0 (en) * 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP2017522311A (ja) 2014-07-16 2017-08-10 ジェネンテック， インコーポレイテッド Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法
JP6986965B2 (ja) * 2014-07-22 2021-12-22 アポロミクス インコーポレイテッド 抗ｐｄ−１抗体
CA2957387A1 (fr) 2014-08-07 2016-02-11 Haruki Okamura Agent therapeutique contre le cancer contenant une combinaison d'il-18 et d'anticorps de ciblage de molecules
US11147652B2 (en) 2014-11-13 2021-10-19 Align Technology, Inc. Method for tracking, predicting, and proactively correcting malocclusion and related issues
RU2753902C2 (ru) * 2014-11-20 2021-08-24 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
HUE050596T2 (hu) * 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
US10227408B2 (en) 2015-02-19 2019-03-12 Compugen Ltd. Anti-PVRIG antibodies and methods of use
CA2980390A1 (fr) * 2015-03-23 2016-09-29 Bayer Pharma Aktiengesellschaft Anticorps anti-ceacam6 et leurs utilisations
KR102876923B1 (ko) * 2015-10-23 2025-10-28 화이자 인코포레이티드 항-il-2 항체 및 조성물 및 이의 용도
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
IL295230A (en) * 2016-03-04 2022-10-01 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
WO2017148424A1 (fr) * 2016-03-04 2017-09-08 四川科伦博泰生物医药股份有限公司 Anticorps anti-pdl-1, composition pharmaceutique et utilisations de celui-ci
CA3020204A1 (fr) 2016-04-07 2017-10-12 Cancer Research Technology Limited Anticorps bispecifiques du recepteur fc gamma anti-cd25 pour la depletion de cellules specifiques d'une tumeur
KR102495601B1 (ko) * 2016-06-10 2023-02-06 리제너론 파마슈티칼스 인코포레이티드 항-gitr 항체 및 그것의 사용
JP6831651B2 (ja) 2016-07-04 2021-02-17 川崎重工業株式会社 ワークの袋詰め装置
WO2018089420A1 (fr) 2016-11-08 2018-05-17 Delinia, Inc. Variants d'il-2 pour le traitement de maladies auto-immunes
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
US11119165B2 (en) 2017-06-28 2021-09-14 North Carolina State University Office of Research Commercialization Photonic band-gap resonator for magnetic resonance applications
JP7225135B2 (ja) 2017-07-06 2023-02-20 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための化合物及び方法
UA129536C2 (uk) 2018-03-13 2025-05-28 Туск Терап'Ютікс Лтд Анти-cd25 для виснаження пухлиноспецифічних клітин
US11814434B2 (en) 2018-03-13 2023-11-14 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
KR20200003558A (ko) 2018-07-02 2020-01-10 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 용지 슬립을 방지하기 위한 급지장치 및 이를 포함하는 화상형성장치
KR102080909B1 (ko) 2018-07-06 2020-02-24 한국수력원자력 주식회사 원자로의 해체 시스템

Also Published As

Publication number Publication date
BR112020016499A2 (pt) 2021-01-26
JP2021533726A (ja) 2021-12-09
PE20210289A1 (es) 2021-02-11
US20210009699A1 (en) 2021-01-14
BR112020016501A2 (pt) 2021-01-26
JP7563978B2 (ja) 2024-10-08
EP3765504A1 (fr) 2021-01-20
US20190322752A1 (en) 2019-10-24
WO2019175223A1 (fr) 2019-09-19
US20190300613A1 (en) 2019-10-03
CA3088659A1 (fr) 2019-09-19
US10752691B2 (en) 2020-08-25
US11802161B2 (en) 2023-10-31
CN112020513A (zh) 2020-12-01
CN112020512A (zh) 2020-12-01
JP2021515565A (ja) 2021-06-24
US11787866B2 (en) 2023-10-17
EP3765507B1 (fr) 2024-04-24
EP3765511C0 (fr) 2024-07-24
WO2019175222A1 (fr) 2019-09-19
SG11202008699WA (en) 2020-10-29
JP7565797B2 (ja) 2024-10-11
JP2021515566A (ja) 2021-06-24
EP3765506A1 (fr) 2021-01-20
WO2019175217A1 (fr) 2019-09-19
TW201938588A (zh) 2019-10-01
US11851494B2 (en) 2023-12-26
AU2019233581A1 (en) 2020-09-03
US20200407454A1 (en) 2020-12-31
US20210009704A1 (en) 2021-01-14
US20210040221A1 (en) 2021-02-11
US10745485B2 (en) 2020-08-18
EP3765506B1 (fr) 2024-04-24
US11814434B2 (en) 2023-11-14
EP3765506C0 (fr) 2024-04-24
US20210009702A1 (en) 2021-01-14
US20210054084A1 (en) 2021-02-25
CN112020515B (zh) 2024-07-16
JP7474701B2 (ja) 2024-04-25
CN112020512B (zh) 2024-12-31
KR20200131286A (ko) 2020-11-23
AU2019233576A1 (en) 2020-09-17
SG11202008784RA (en) 2020-10-29
EP3765502A1 (fr) 2021-01-20
EP3765504B1 (fr) 2024-07-31
EP3765504C0 (fr) 2024-07-31
KR20200131862A (ko) 2020-11-24
EP3765511A1 (fr) 2021-01-20
EP3765505B1 (fr) 2023-09-27
CN112020516B (zh) 2025-01-03
US20190284287A1 (en) 2019-09-19
AU2019233575A1 (en) 2020-09-17
CA3088671A1 (fr) 2019-09-19
EP3765502C0 (fr) 2024-08-07
US11697688B2 (en) 2023-07-11
US11802160B2 (en) 2023-10-31
JP7510348B2 (ja) 2024-07-03
EP3765505C0 (fr) 2023-09-27
CN112074536A (zh) 2020-12-11
EP3765511B1 (fr) 2024-07-24
US11919960B2 (en) 2024-03-05
EP3765510A1 (fr) 2021-01-20
WO2019175226A1 (fr) 2019-09-19
JP2021516974A (ja) 2021-07-15
CN112020516A (zh) 2020-12-01
WO2019175224A1 (fr) 2019-09-19
JP2021515568A (ja) 2021-06-24
CR20200465A (es) 2020-11-17
AU2019233581B2 (en) 2025-08-28
US20210047420A1 (en) 2021-02-18
KR20200131861A (ko) 2020-11-24
WO2019175216A1 (fr) 2019-09-19
EP3765507A1 (fr) 2021-01-20
JP2021516973A (ja) 2021-07-15
US11873341B2 (en) 2024-01-16
WO2019175220A1 (fr) 2019-09-19
US20210009703A1 (en) 2021-01-14
EP3765502B1 (fr) 2024-08-07
JP7451414B2 (ja) 2024-03-18
JP2021516975A (ja) 2021-07-15
CN112218891A (zh) 2021-01-12
JP2021516976A (ja) 2021-07-15
EP3765503B1 (fr) 2024-05-01
TW201940515A (zh) 2019-10-16
CN112074536B (zh) 2024-09-10
CN112020515A (zh) 2020-12-01
CN112020513B (zh) 2024-08-16
CR20200467A (es) 2020-11-17
PE20210288A1 (es) 2021-02-11
WO2019175215A1 (fr) 2019-09-19
EP3765503A1 (fr) 2021-01-20
JP7451415B2 (ja) 2024-03-18
KR102909650B1 (ko) 2026-01-08
EP3765503C0 (fr) 2024-05-01
CN112020514A (zh) 2020-12-01
EP3765505A1 (fr) 2021-01-20
CA3088246A1 (fr) 2019-09-19
CR20200466A (es) 2020-11-11
BR112020016519A2 (pt) 2020-12-15
TW202003034A (zh) 2020-01-16
PE20210287A1 (es) 2021-02-11
EP3765507C0 (fr) 2024-04-24
JP7563979B2 (ja) 2024-10-08
CN112041345B (zh) 2025-01-03
SG11202008733YA (en) 2020-10-29
CN112020514B (zh) 2024-08-20
CN112218891B (zh) 2024-07-16
CN112041345A (zh) 2020-12-04
US10738125B2 (en) 2020-08-11

Similar Documents

Publication Publication Date Title
MA51993A (fr) Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur
MA46668A (fr) Cellules présentatrices d'antigènes artificielles génétiquement modifiées pour l'expansion de l'infiltration lymphocytaire intratumorale
EP3759218A4 (fr) Méthodes et compositions pour vecteurs viraux évitant les anticorps
MA53330A (fr) Constructions d'anticorps pour cldn18.2 et cd3
IL281232A (en) Chimeric antigen receptor for solid cancer and t cells expressing chimeric antigen receptor
EP4161536A4 (fr) Nouvelles constructions pour récepteurs antigéniques chimériques
EP3784699A4 (fr) Anticorps anti-tl1a optimisés
IL288153A (en) Stabilized formulations containing anti-angptl3 antibodies
EP3612210A4 (fr) Cellules immunitaires exprimant des récepteurs d'antigènes modifiés
EP3470424A4 (fr) Séquence de région constante à chaîne lourde d'anticorps pour améliorer l'activité d'anticorps agonistes
MA71409A (fr) Constructions d'anticorps pour dll3 et cd3
EP3341406A4 (fr) Récepteurs d'antigène chimérique conditionnellement actifs pour cellules t modifiées
MX389021B (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MA52545A (fr) Anticorps pour radionucléides chélatés
EP3807318A4 (fr) Constructions d'anticorps multi-spécifiques
MA38632A1 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
EP3847195A4 (fr) Cellules de récepteur d'antigène chimérique pour le traitement d'une tumeur solide
MA51903A (fr) Formulations d'anticorps b7-h4
EP3752536A4 (fr) Anticorps anti-her2
EP3885367A4 (fr) Anticorps bispécifique anti-her2/pd1
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
PH12021550096A1 (en) Compositions of fcrn antibodies and methods of use thereof
EP3990495A4 (fr) Anticorps pour l'activation de lymphocytes t
EP3532078A4 (fr) Cellules présentatrices d'antigène artificielles utilisées pour l'expansion de cellules immunitaires pour l'immunothérapie
EP3880710A4 (fr) Anticorps anti-cd73 activant les lymphocytes b